Cargando…

Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa

INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashi, Murielle Longokolo, Mambimbi, Marcel Mbula, Situakibanza, Hippolyte Nani-Tuma, Ndona, Madone Mandina, Risassi, Jean-Robert Makulo, Ngongo, Nadine Mayasi, Bepouka, Ben, Ossam, Odio, Tshibola, Jean Mukaya, Tshienda, Frédéric Tshibasu, Kasongo, Eric Mukenge, Nzita, Mamy Ngole, Tuna, Lukiana, Lulebo, Aimée, Sonzi, Donatien Mangala, Lusunsi, Christian Kisoka, Longo-Mbenza, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460102/
https://www.ncbi.nlm.nih.gov/pubmed/37637394
http://dx.doi.org/10.11604/pamj.2023.45.63.39461
Descripción
Sumario:INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compared to other antiretrovirals in predicting atherosclerosis in people living with HIV (PLHIV) and hospitalized in Kinshasa Hospital. METHODS: we conducted an interventional study of people living with HIV who had received antiretroviral therapy (ART) for at least 6 months and were treated in the structures of the network coordinated by the Catholic Church (BDOM-Bureau Diocésain des Oeuvres Médicales) and of the University Clinics of Kinshasa (CUK) between January 2017 and December 2021. Subclinical atherosclerosis was defined as Pulsed Pressure (PP) ≥60 mm Hg; Carotid Intima-Media Thickness (CIMT) > 0.8 mm; and Systolic Pressure Index (SPI) < 0.9. Logistic regression was used in the statistical analysis of associations. RESULTS: a total of 334 PLHIV were recruited, of whom 96.1% (n=321) were on ART and 13.9% (n=13) were ART naïve patients. The mean age of PLHIV was 51±12 years with a female predominance (70.4%; n=235); the independent determinants of subclinical atherosclerosis were marital status (aOR: 4. 95% CI 1.5-10.5; p<0.006), low socioeconomic level (aOR: 10.7, 95% CI 2.3-48.7 p<0.002), duration of HIV infection (aOR: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral therapy ≥9 years (aOR: 0.3, 95% CI 0.2-0.7; p<0.005) and total cholesterol ratio/high-density lipoprotein-cholesterol (CT/HDL-c)(aOR: 2, 95% CI 1.1-3.6; p= 0.034). The mean values of traditional and emergent variables were significantly higher in the previous ART regimen without DTG than in the new regimen with DTG. However, dyslipidemia was detected during the new DTG-based regimen. CONCLUSION: dyslipidemia was common during the DTG-based regimen. Marital status, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9 years and the TC/HDL-c ratio were identified as determinants of subclinical atherosclerosis in PLHIV on ART hospitalized in the Kinshasa hospital.